Edition:
India

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

114.15USD
20 Jan 2017
Change (% chg)

$-0.05 (-0.04%)
Prev Close
$114.20
Open
$114.67
Day's High
$115.01
Day's Low
$114.08
Volume
3,413,646
Avg. Vol
2,345,864
52-wk High
$126.07
52-wk Low
$94.30

JNJ.N

Chart for JNJ.N

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company's segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care,... (more)

Overall

Beta: 0.75
Market Cap(Mil.): $310,684.69
Shares Outstanding(Mil.): 2,720.53
Dividend: 0.80
Yield (%): 2.80

Financials

  JNJ.N Industry Sector
P/E (TTM): 20.02 29.62 30.50
EPS (TTM): 5.71 -- --
ROI: 14.16 15.43 14.85
ROE: 22.09 16.61 16.27

Sanofi's M&A misses frustrate some investors in drugmaker

PARIS/DAVOS, Switzerland For the last year, Sanofi's chief executive has made clear his quest for deals to help revive the fortunes of France's biggest drugmaker.

20 Jan 2017

Sanofi's M&A misses frustrate some investors in drugmaker

PARIS/DAVOS, Switzerland For the last year, Sanofi's chief executive has made clear his quest for deals to help revive the fortunes of France's biggest drugmaker.

20 Jan 2017

INSIGHT: Sanofi's M&A misses frustrate some investors in drugmaker

PARIS/DAVOS, Switzerland For the last year, Sanofi's chief executive has made clear his quest for deals to help revive the fortunes of France's biggest drugmaker.

20 Jan 2017

INSIGHT-Sanofi's M&A misses frustrate some investors in drugmaker

* Investors growing impatient after it fails to land acquisitions

20 Jan 2017

BRIEF-Johnson & Johnson reports 7.4 pct stake in Merus NV as of Dec 31, 2016

* Johnson & Johnson reports 7.4 percent passive stake in Merus NV as of Dec 31, 2016 - SEC filing Source text: (http://bit.ly/2j9ZI8k) Further company coverage:

19 Jan 2017

EU mergers and takeovers (Jan 18)

BRUSSELS, Jan 18 The following are mergers under review by the European Commission and a brief guide to the EU merger process:

18 Jan 2017

BRIEF-Orthocell announces collaboration with Johnson & Johnson

* Orthocell announces collaboration with Johnson & Johnson Innovation

12 Jan 2017

Japan's Takeda ready for fresh acquisitions after $5.2 billion Ariad deal

TOKYO Japan's Takeda Pharmaceutical Co flagged its appetite for fresh acquisitions to bolster its drug portfolio after agreeing on Monday to acquire cancer drug maker Ariad Pharmaceuticals in a $5.20 billion deal.

10 Jan 2017

UPDATE 2-Japan's Takeda ready for fresh acquisitions after $5.2 bln Ariad deal

* Takeda able to limit debt, retain credit rating post Ariad deal-CFO

10 Jan 2017

Deals of the day- Mergers and acquisitions

Jan 6 The following bids, mergers, acquisitions and disposals were reported by 2120 GMT on Friday:

07 Jan 2017

Earnings vs. Estimates